330 related articles for article (PubMed ID: 23428899)
1. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
[TBL] [Abstract][Full Text] [Related]
2. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
3. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
[TBL] [Abstract][Full Text] [Related]
4. CMV-specific TCR-transgenic T cells for immunotherapy.
Schub A; Schuster IG; Hammerschmidt W; Moosmann A
J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
[TBL] [Abstract][Full Text] [Related]
5. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
7. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
9. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen.
Luo W; Zhang XB; Huang YT; Hao PP; Jiang ZM; Wen Q; Zhou MQ; Jin Q; Ma L
J Mol Med (Berl); 2011 Sep; 89(9):903-13. PubMed ID: 21556811
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
11. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
12. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
13. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
[TBL] [Abstract][Full Text] [Related]
14. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
16. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
18. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.
Perro M; Tsang J; Xue SA; Escors D; Cesco-Gaspere M; Pospori C; Gao L; Hart D; Collins M; Stauss H; Morris EC
Gene Ther; 2010 Jun; 17(6):721-32. PubMed ID: 20164855
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.
Yang D; Shao Q; Sun H; Mu X; Gao Y; Jiang R; Hou J; Yao K; Chen Y; Sun B
Clin Dev Immunol; 2011; 2011():716926. PubMed ID: 21969838
[TBL] [Abstract][Full Text] [Related]
20. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
Berthoud TK; Hamill M; Lillie PJ; Hwenda L; Collins KA; Ewer KJ; Milicic A; Poyntz HC; Lambe T; Fletcher HA; Hill AV; Gilbert SC
Clin Infect Dis; 2011 Jan; 52(1):1-7. PubMed ID: 21148512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
